We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

32 hedge funds and large institutions have $73.2M invested in TScan Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 1

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

14% more funds holding

Funds holding: 28 → 32 (+4)

6.94% more ownership

Funds ownership: 58.72% → 65.66% (+6.9%)

5% more capital invested

Capital invested by funds: $69.9M → $73.2M (+$3.32M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
32
Holders Change
+4
Holders Change %
+14.29%
% of All Funds
0.51%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
10
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$973K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$918K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$446K
4
Morgan Stanley
Morgan Stanley
New York
+$352K
5
Northern Trust
Northern Trust
Illinois
+$133K

Top Sellers

1
MIM
Monashee Investment Management
Massachusetts
-$1M
2
Renaissance Technologies
Renaissance Technologies
New York
-$303K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
1
Lynx1 Capital Management
Puerto Rico
$13.4M – – –
EC
2
EcoR1 Capital
California
$12.8M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$10.2M – – –
BI
4
BVF Inc
California
$7.65M – – –
BBA
5
Baker Bros. Advisors
New York
$7.13M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$4.49M +$918K +393,305 +29%
BlackRock
7
BlackRock
New York
$4.3M +$973K +416,996 +33%
DMC
8
Deer Management Company
New York
$3.19M – – –
AI
9
Alphabet Inc
California
$2.76M – – –
SAM
10
Simplify Asset Management
Nevada
$2.68M – – –
DF
11
DC Funds
Virginia
$1.61M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$789K +$446K +191,047 +163%
Morgan Stanley
13
Morgan Stanley
New York
$664K +$352K +150,972 +139%
Stifel Financial
14
Stifel Financial
Missouri
$299K +$41.8K +17,900 +18%
NW
15
NewEdge Wealth
Pennsylvania
$234K – – –
BCM
16
Bridgeway Capital Management
Texas
$226K +$89.4K +38,300 +77%
Northern Trust
17
Northern Trust
Illinois
$184K +$133K +56,921 +378%
State Street
18
State Street
Massachusetts
$107K +$7.47K +3,200 +8%
DIM
19
DC Investments Management
Virginia
$91K – – –
LBA
20
Letko, Brosseau & Associates
Quebec, Canada
$82.9K +$75.6K +32,400 New
American Century Companies
21
American Century Companies
Missouri
$49.2K +$44.8K +19,212 New
Renaissance Technologies
22
Renaissance Technologies
New York
$45K -$303K -129,762 -88%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$43.3K +$39.5K +16,915 New
PFCS
24
Pale Fire Capital SE
Czech Republic
$42.4K +$38.7K +16,575 New
PFMU
25
Privium Fund Management (UK)
United Kingdom
$41.5K – – –
1
2

TCRX Hedge Fund Activity: Q3 2023 in Review

32 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q3 2023, worth a combined $73.2M — up 4.7% from $69.9M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TCRX positions and 1 closed out — a net gain of 5 holders — while 10 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, adding an estimated $973K. The largest seller was Monashee Investment Management, exiting entirely with an estimated $1M sold.

  • 32 institutional investors held TScan Therapeutics (TCRX) as of Q3 2023, up from 28 in Q2 2023.
  • Funds reported $73.2M of TScan Therapeutics stock for Q3 2023, up 4.7% quarter-over-quarter.
  • 6 funds opened new TScan Therapeutics positions in Q3 2023 and 1 closed out, a net change of +5 holders.
  • The largest TScan Therapeutics buyer in Q3 2023 was BlackRock, an estimated $973K added.
  • The largest TScan Therapeutics seller in Q3 2023 was Monashee Investment Management, an estimated $1M sold.

Based on aggregated 13F filings for Q3 2023.